Cannabidiol monotherapy for treatment-resistant schizophrenia
Antônio Waldo Zuardi(Universidade de São Paulo), José Alexandre S. Crippa(Universidade de São Paulo), Richard E. Musty(University of Vermont), Rafael Faria Sanches(Universidade de Ribeirão Preto), Serdar Dursun(Centre for Addiction and Mental Health), Jaime E. C. Hallak(Conselho Nacional de Desenvolvimento Científico e Tecnológico), Silvio Luiz Morais(Universidade de São Paulo)
Cited by 192
Related Papers
Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology
|American Journal of Psychiatry|2016|1.1k
Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial
|Psychological Medicine|2018|819
Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients
|Neuropsychopharmacology|2011|763
Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report
|Journal of Psychopharmacology|2010|530
Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report
|Brazilian Journal of Psychiatry|2015|484